Top-Line Results Show Alirocumab Reduces Frequency and Need for Apheresis in Patients with Heterozygous FH
Top-line results from the phase 3 ODYSSEY ESCAPE trial, which evaluated 62 patients with heterozygous familial hypercholesterolemia (HeFH) who required chronic, weekly, or biweekly apheresis therapy, have shown that the PCSK9 inhibitor alirocumab reduced the frequency of apheresis by 75% compared with placebo, and eliminated the need for apheresis for 63% of patients in the […]
